Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from LTR Pharma Limited ( (AU:LTP) ) is now available.
LTR Pharma Limited has completed an extractables study for its intranasal spray, SPONTAN, used for erectile dysfunction, and has initiated a leachables study as part of its FDA regulatory submission process. The completion of these studies marks a significant milestone in LTR Pharma’s regulatory development program, ensuring that the packaging materials do not compromise product safety or efficacy. This progress supports the company’s strategy to advance SPONTAN through the regulatory pathway and build commercial foundations for its products, including a planned entry into the US market.
More about LTR Pharma Limited
LTR Pharma is an emerging pharmaceutical company focused on developing and commercializing innovative therapies to address significant unmet medical needs. The company utilizes a proprietary intranasal drug delivery platform to offer rapid, non-invasive treatment options across various therapeutic areas. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, while OROFLOW is under development for oesophageal motility disorders.
Average Trading Volume: 553,270
Technical Sentiment Signal: Sell
For detailed information about LTP stock, go to TipRanks’ Stock Analysis page.